Key result
Early dapagliflozin reduces MACE by ~74% in patients with early-onset post-MI heart failure.
Why the study?
To investigate the effects of dapagliflozin added to standard therapy on heart rate variability, sST2, NT-proBNP, and echocardiographic parameters in patients with early-onset post-myocardial infarction heart failure.
Does dapagliflozin 10 mg daily improve heart rate variability, cardiac function, and short-term prognosis in patients with early-onset post-myocardial infarction heart failure?
RCT (n=98)
Single-blind
Computer-generated random number table
No
Does dapagliflozin 10 mg daily improve heart rate variability, cardiac function, and short-term prognosis in patients with early-onset post-myocardial infarction heart failure?
Odds Ratio: 0.265 (95% CI 0.097–0.724)
Absolute Event Rate: 8% vs 29.17%
p-value: p=0.010
In patients with early-onset post-myocardial infarction heart failure, adding dapagliflozin 10 mg daily to standard therapy significantly improves surrogate markers of cardiac and autonomic function and reduces the short-term risk of major adverse cardiovascular events.
Supports early dapagliflozin in post-MI HF; extends SGLT2i evidence to the acute phase.
Objective To investigate the effects of dapagliflozin, in addition to standard therapy, on heart rate variability (HRV), soluble growth stimulation expressed gene 2 protein (sST2), N-terminal pro B-type natriuretic peptide (NT-proBNP), and echocardiographic parameters in patients with early-onset post-myocardial infarction heart failure (HF). Methods A total of 98 patients with early-onset post-myocardial infarction HF were enrolled and randomly divided into a control group ( n = 48, receiving standard therapy) and an observation group ( n = 50, receiving standard therapy plus dapagliflozin 10 mg daily). HRV, cardiac function, and echocardiographic parameters were measured at baseline and after 24 weeks of treatment. Short-term prognosis and adverse events were also monitored. Results Compared with the control group, the observation group showed significantly greater improvements in SDNN and SDANN ( P < 0.05). Significant improvements were also observed in sST2 and NT-proBNP levels in the observation group compared to the control group ( P < 0.05). Additionally, echocardiographic parameters, including EF, LVESD, LVEDD, IVST, LVMI, and E/e’, showed greater improvement in the observation group ( P < 0.05). The incidence of major adverse cardiovascular events was lower in the observation group ( P < 0.05). Multivariate logistic regression model revealed that dapagliflozin use was independently associated with a reduced risk of MACE (OR = 0.265, 95% CI: 0.097–0.724, P = 0.010). Conclusion Early administration of dapagliflozin 10 mg, in addition to standard therapy, can improve autonomic function, cardiac function, and short-term prognosis in patients with early-onset post-myocardial infarction heart failure.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2025) conducted an RCT in Early-onset post-myocardial infarction heart failure (n=98). Dapagliflozin vs. Standard therapy was evaluated on Major adverse cardiovascular events (MACE) (OR 0.265, 95% CI 0.097-0.724, p=0.010). Early administration of dapagliflozin 10 mg daily significantly reduced the risk of major adverse cardiovascular events (OR 0.265) in patients with early-onset post-myocardial infarction heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: